All In Biotech

Drug Trial Radar · NCT07686068

First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors

Phase 1/2a Open-Label Clinical Trial Evaluating VBC106, an FRα- and MSLN-Directed Bispecific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Aug 18, 2026

Primary completion

Dec 1, 2028

Study completion Dec 1, 2028

Sponsor

Lead sponsor
VelaVigo Bio IncIndustry
Sponsor type
Industry
First posted
Jul 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC106.

Conditions

  • Participants With Advanced Solid Tumor Malignancies

Interventions

  • VBC106Drug

    VBC106

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLT) as defined in the protocolTime frame: (DLT)From time of first dose of VBC106 to end of DLT period (approximately 21 days)
  2. Incidence of Serious Adverse EventsTime frame: From time of Informed Consent to 30 days post last dose of VBC106
  3. Incidence of Adverse Events (AEs)Time frame: From time of Informed Consent to 30 days post last dose of VBC106

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • NEXT Oncology Houston

    Houston, Texas

  • START Mountain Region, LLC.

    West Valley City, Utah

  • NEXT Oncology Virginia

    Fairfax, Virginia

  • Icon Cancer Centre Wesley

    Brisbane, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.